Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 1 Interim Condensed Consolidated Statements of Comprehensive Income 2 Interim Condensed Consolidat

Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2024

Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange Commission in the United States is c o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, +1 (617) 337-4701.

Unaudited Interim Condensed Consolidated Financial Statements

Operating and Financial Review and Prospects

Unaudited Interim Condensed Consolidated Financial Statements

Interim Condensed Consolidated Statements of Profit or Loss

(1) Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (please see Note 4.2 for further details).

The accompanying notes form an integral part of these interim consolidated financial statements.

Interim Condensed Consolidated Statements of Comprehensive Income

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Financial Position

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Changes in Stockholders' Equity

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Cash Flows

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Selected Explanatory Notes to the Unaudited Interim Condensed Consolidated Financial Statements

1.Corporate Information

BioNTech SE is a limited company incorporated and domiciled in Germany. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying unaudited interim condensed consolidated financial statements present the financial position and the results of operation of BioNTech SE and its subsidiaries and have been prepared on a going concern basis in accordance with the International Financial Reporting Standards, or IFRS as issued by the International Accounting Standards Board, or IASB. References to the "Company", "BioNTech", "Group", "we", "us" and "our" refer to BioNTech SE and its consolidated subsidiaries.

We are a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical need and major global health burden. Our fully integrated model combines decades of research in immunology, translational drug discovery and development, a technology agnostic innovation engine, GMP manufacturing, and commercial capabilities to rapidly discover, develop and commercialize our marketed product and other candidate vaccines and therapies. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational mRNA vaccines and therapeutics, cell and gene therapies, targeted antibodies and small molecule immunomodulators.

Our unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2024, were authorized for issuance in accordance with a resolution of the audit committee on May 3, 2024.

2.Basis of Preparation, Significant Accounting Policies and further Accounting Topics

Basis of Preparation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2024, have been prepared in accordance with International Accounting Standard (IAS) 34 Interim Financial Reporting.

The unaudited interim condensed consolidated financial statements do not include all the information and disclosures required in the audited consolidated financial statements, and should be read in conjunction with our audited consolidated financial statements and accompanying notes included in our Annual Report on Form 20-F as of and for the year ended December 31, 2023.

We prepare and present our unaudited interim condensed consolidated financial statements in Euros and round numbers to millions of Euros. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations.

The unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2024, include BioNTech SE and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Significant Accounting Judgments, Estimates and Assumptions and Accounting Policies

The preparation of the unaudited interim condensed consolidated financial statements requires our management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. This includes but is not limited to our judgment relating to our collaboration with Pfizer, Inc., or Pfizer, as described under the subheading "Pfizer Agreement Characteristics" in Note 3 to our audited consolidated financial statements as of and for the year ended December 31, 2023. In order to determine our share of the collaboration partner's gross profits, we used certain information from the collaboration partner, including revenues from the sale of products and certain other sharable expense items, some of which is based on preliminary data shared between the partners.

Our management continually evaluates judgments and estimates, including those related to contingencies, fair value measurement of derivatives, revenues and expenses. Management bases its judgments and estimates on parameters available at the time when the unaudited interim condensed consolidated financial statements were prepared. Existing

circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond our control. Such changes are reflected in the assumptions when they occur.

The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of our audited consolidated financial statements as of and for the year ended December 31, 2023, except for income taxes, which are accounted for using the expected annual tax rate in our unaudited interim condensed consolidated financial statements (see Note 5).

Furthermore, we recognize acquired contractual rights to cash flows from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies as royalty assets. Since we do not own the intellectual property or have the right to commercialize the underlying products, royalty assets are recognized as financial assets measured at fair value through profit and loss. We recognize day one gains and losses only when the fair value is evidenced by a quoted price in an active market for the same instrument or is based on a valuation technique that only uses data from observable markets. In all other cases, we defer the difference between the fair value at initial recognition and the transaction price. After initial recognition, we recognize that deferred difference as a gain or loss only to the extent that it arises from a change in a factor that market participants would take into account when pricing the asset or liability.

Standards Applied for the First Time

The IFRS standards applied for the first time as of January 1, 2024, as disclosed in the notes to the audited consolidated financial statements as of and for the year ended December 31, 2023, had no impact on our unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2024.

3.Revenues from Contracts with Customers

Disaggregated information on revenues

Set out below is the disaggregation of our revenues from contracts with customers

COVID-19 Vaccine Revenues

During the three months ended March 31, 2024 and 2023, commercial revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide, mainly comprising our share of the collaboration partner's gross profit derived from sales in the collaboration partner's territory. Overall, our commercial COVID-19 vaccine revenues amounted to 124.2 million during the three months ended March 31, 2024, compared to 1,263.5 million for the comparative prior year period. The year-over-year change was mainly due to lower revenues from the sales of our COVID-19 vaccines worldwide resulting from lower sales demand during the three months ended March 31, 2024.

During the three months ended March 31, 2024, our other revenues were mainly derived from a pandemic preparedness contract effectively supplemented in the first quarter of 2024 with the German government.

Revenues from contracts with customers were recognized as follows

(1) Represents sales based on the share of the collaboration partners' gross profit.

4.Income and Expenses

From the three months ended March 31, 2023, to the three months ended March 31, 2024, cost of sales decreased by 36.9 million or 38% from 96.0 million to 59.1 million, mainly due to recognizing lower cost of sales from our decreased COVID-19 vaccine sales, which included the share of gross profit that we owe our collaboration partner, Pfizer, and royalty expenses based on our sales. In addition, cost of sales was impacted by expenses arising from inventory write-downs to net realizable value due to inventories expected to be unsellable, not fulfilling the specification defined by our quality standards, shelf-life expiry or destruction of inventory amounting to 36.0 million, compared to 73.7 million in the previous period. The inventories valued at net realizable value in our consolidated statement of financial position as of March 31, 2024, take contractual compensation payments into consideration.

Research and Development Expenses

From the three months ended March 31, 2023, to the three months ended March 31, 2024, our research and development expenses increased by 173.5 million or 52%, from 334.0 million to 507.5 million, mainly influenced by progressing clinical studies for pipeline candidates and our newly acquired clinical stage antibody drug conjugate (ADC) and antibody product candidates which further expand our oncology pipeline. Further contributions to the increase coming from wages, benefits and social security expenses resulting from a significant increase in headcount.

General and Administrative Expenses

From the three months ended March 31, 2023, to the three months ended March 31, 2024, our general and administrative expenses increased by 5.2 million or 5%, from 111.8 million to 117.0 million, primarily driven by increased expenses for IT environment and wages, benefits, and social security expenses resulting from a significant increase in headcount.

4.2Other Operating Expenses

Other operating expenses recognized during the three months ended March 31, 2024 and 2023 are shown in the following table

(1) Adjustments to prior-year figures relate to reclassifying legal costs in connection with certain litigation as other operating expenses, rather than general and administrative expenses, to reflect changes in reporting.

During the three months ended March 31, 2024, other operating expenses decreased compared to the three months ended March 31, 2023, primarily because the foreign exchange differences arising on operating items changed from a negative effect to a positive effect, which is recorded in other operating income during the three months ended March 31, 2024 (see Note 4.3).

4.3Other Operating Income

Other operating income recognized during the three months ended March 31, 2024 and 2023 is shown in the following table

During the three months ended March 31, 2024, other income decreased compared to the three months ended March 31, 2023, as the result on derivative instruments at fair value through profit or loss arising on foreign exchange forward contracts that did not qualify for hedge accounting changed from a gain to a loss, which is recorded in other operating expenses (see Note 4.2).

The finance result recognized during the three months ended March 31, 2024 and 2023 is shown in the following table

During the three months ended March 31, 2024 and 2023, the finance result was mainly derived from interest income in relation to bank deposits and debt security investments as well as fair value adjustments of our money market funds.

For the three months ended March 31, 2024, income taxes were calculated based on the best estimate of the weighted average annual income tax rates expected for the full financial years (estimated annual effective income tax rates) on ordinary income before tax adjusted by the tax effect of any discrete items. The income tax asset represents the portion of prepayments for corporate income taxes and trade taxes in Germany that have been paid for the first quarter of 2024 but not yet offset by income tax expenses calculated for such quarter. For the three months ended March 31, 2024, our effective income tax rate was approximately 5.0% applicable on our negative income and for the three months ended March 31, 2023, our effective income tax rate was approximately 29.0%, on our positive income. The decrease in the effective income tax rate was mainly driven by the expected negative result for 2024 and management's assessment of the requirements in IAS 12, including on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. Thus, in countries where the requirements of IAS 12 were not fulfilled, no deferred tax asset was recognized. Such assessment takes into account the

fact that there is an inherent risk of failure in pharmaceutical development and uncertainty of approvals that depend on external regulatory agencies' opinions.

As of March 31, 2024, it is considered highly probable that taxable profits for the U.S. tax group will be available against which the deferred tax assets can be utilized in the near future fulfilling the requirements set out by IAS 12.

We apply the mandatory exception to recognizing and disclosing information about deferred tax assets and liabilities arising from Pillar Two income taxes. Furthermore, we reviewed the corporate structure in light of the introduction of Pillar Two Model Rules in various jurisdictions. Since the Group's relevant effective tax rate calculated for Pillar Two Purposes is mainly above 15% in all jurisdictions in which it operates, it has been determined that the Group is not materially subject to Pillar Two "top-up" taxes. Therefore, the consolidated financial statements for the three months ended March 31, 2024, do not include information required by paragraphs 88A-88D of IAS 12.

Income taxes recognized during the three months ended March 31, 2024 and 2023 are shown in the following table

6.Financial Assets and Financial Liabilities

Financial Assets and Liabilities at Amortized Cost and at Fair Value through OCI and Profit or Loss

Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated

(1) Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value.

The 195.3 million increase in listed equity investments compared to year-end 2023 mainly reflects our investment in Autolus Therapeutics plc (Autolus) in February 2024.

Under the terms of the license and option agreement with Autolus we acquired a royalty asset in connection with Autolus' lead cell therapy candidate, obe-cel, and we are eligible to receive a royalty on obe-cel net sales. Autolus will retain full rights to and control of the development and commercialization of obe-cel. We deferred a day one gain amounting to 5.6 million based as the difference of the measured fair value of the instrument at initial recognition based on the present value of expected future cash flows and the transaction price.

Additional developments in our financial assets and liabilities mainly resulted from growth and reallocation of existing capital. This led to a decrease of 3,386.8 million in money market funds and increases of 1,973.0 million in security investments and 1,275.5 million in bank deposits compared to year-end 2023.

(1) Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are not disclosed because the book values represent a reasonable approximation of fair value.

Equity investments designated at Fair Value through OCI

Financial investments in equity securities measured at fair value through other comprehensive income comprise the following effects

Measurement of fair values

The following table shows the valuation techniques used in measuring fair values for financial instruments in our consolidated statements of financial position, as well as the significant unobservable inputs used.

Recurring Fair Values (Level 3)

The following table shows the recurring fair value measurement of contingent consideration and royalty assets as well as the effect of the measurements on our unaudited interim condensed consolidated statements of profit or loss for the current period.

The sensitivity of the fair values of contingent consideration to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table

Contingent consideration

The sensitivity of the fair values of royalty assets to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table